Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HydrogenFAST
NCT05574296Phase 1Recruiting
- Sponsor
- Boston Children's Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Molecular hydrogen in reperfusion injury (IRI) and cardiac arrest (SCA) (2 arms), sponsored by Boston Children's Hospital. Primary endpoints: Feasibility of hydrogen administration at 72 hours and Safety of hydrogen administration at 30 days. Started Mar 2024; status: recruiting.
02
Drugs
Molecular hydrogen
03
Conditions
reperfusion injury (IRI)cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT05574296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574296.